Abeona Therapeutics Partners with Beacon for Gene Therapy Evaluation in Ophthalmic Conditions
Thursday, 11 July 2024, 15:05
Abeona Collaborates with Beacon for Gene Therapy Research in Ophthalmic Conditions
Abeona Therapeutics (ABEO) has signed a research agreement with Beacon to assess the efficacy of its gene therapy technology in treating ophthalmic disorders. This collaboration aims to leverage innovative gene therapy approaches to address vision-related conditions. The partnership signifies a strategic move towards advancing treatment options for eye ailments, with a focus on cutting-edge technology and research in the field.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.